Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LXH254 · 1 trial · 1 indication
Confirmed ORR using RECIST v1.1, per local assessment
| Arm | Type | Description |
|---|---|---|
| LXH254 + LTT462 | EXPERIMENTAL | - |
| LXH254 + trametinib | EXPERIMENTAL | - |
| LXH254 + ribociclib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LXH254 | DRUG | LXH254 will be supplied as tablet for oral use. |
| LTT462 | DRUG | LTT462 will be supplied as hard gelatin capsule for oral use. |
| Trametinib | DRUG | Trametinib will be supplied as film-coated tablet for oral use |
| Ribociclib | DRUG | Ribociclib will be supplied in tablets and hard gelatin capsules. |
Inclusion Criteria: Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight \> 40kg Histologically confirmed unresectable or metastatic cutaneous melanoma Previously treated for unresectable or metastatic melanoma: * Participants with NRAS mutation: * Participants must h...
Top 20 of 50 competitors
LXH254 is an investigational small molecule being studied for the treatment of melanoma. It is currently in Phase 2 clinical development for patients with previously treated unresectable or metastatic melanoma. The drug is being evaluated in combination with other agents to assess its efficacy and safety in this patient population.
LXH254 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the drug's potential as a treatment for melanoma.
LXH254 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is studying the drug in combination with other treatments for patients with previously treated unresectable or metastatic melanoma.
LXH254 is being studied in a Phase 2 clinical trial with the identifier NCT04417621. This trial is titled 'Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma' and is currently active but not recruiting. The trial has an enrollment of 134 participants.
No, LXH254 is not an approved treatment for melanoma. It is an investigational drug currently in Phase 2 clinical trials. The drug is being studied for its efficacy and safety in patients with previously treated unresectable or metastatic melanoma, but it has not yet received regulatory approval.
LXH254 is a small molecule being developed by Novartis for the treatment of melanoma. The specific molecular target of LXH254 has not been disclosed in the available information. The drug is being evaluated in combination with other agents in a Phase 2 clinical trial for patients with previously treated unresectable or metastatic melanoma.